Stock detail
Allogene Therapeutics, Inc.
ALLO
NASDAQ
Risk: loading...
$1.93
▼
-0.07
(-3.50%)
XMarketRadar Scores
durability, valuation, growth, and momentum
Loading scores...
Investment Snapshot
healthy, risky, or unavailable signals
Loading investment snapshot...
Data summary only, not investment advice or a price target.
Technical Workbench signals, CAN SLIM, indicators, and backtests
Rule-based signal from real indicators, not a price prediction
Loading...
CAN SLIM score from quarterly EPS, profit growth, relative strength, and volume
Loading...
Current price position inside recent trading ranges
Loading price ranges...
Dual-timeframe Williams %R reversal signal plus historical forward-return backtest
Loading...
Moving averages, oscillators, performance ranges, and classic pivots
Loading technical analysis...
Fundamental Workbench quarter, ratios, valuation, dividends, events, and source audit
Latest Quarter
Loading...
Quick context
Latest filed quarter, current OHLC, and watchlist actions now live at the top so this section can stay focused on business quality.
Valuation, growth, quality, and relative-return metrics from synced data
Loading key metrics...
Own-history valuation band, DuPont ROE, and sector ranks
Loading...
Reverse percentile of current P/E and P/B against synced historical valuation snapshots
Loading buy/sell zone...
Same-sector comparison: valuation, quality, leverage, and 1Y performance against peers
Loading peer outlook...
Loading...
Loading...
Governance disclosures are not available for NASDAQ yet.
SAST, promoter pledge, NSE bulk/block deals, credit ratings, and NSE/BSE governance filings are India-specific, so they are hidden for this market. Verified international governance data will appear here when a supported source is configured.
Chart
Latest quarter
Loading results...
Events watch
Loading events...
Forecaster Dashboard filing trend, rule-based outlook, and quarterly matrix
Not analyst consensus
Loading forecast dashboard...
Uses synced financial filings and XMarketRadar rule-based signals. External analyst estimates/price targets are shown as unavailable until a licensed estimates feed is configured.
Financials Explorer figures in ₹ crore, except EPS/%
Loading...
News
Loading…